secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0000950170-25-038742
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics reports FY2024 net loss $93.4M; ENLIGHTEN 2 top-line data expected Q2 2025
--------------------------------------------------------------------------------

- Net loss for FY2024 was $93.4M ($1.43 diluted EPS) vs $62.7M in FY2023; cash $40.6M as of Dec 31, 2024.
- Top-line results from ENLIGHTEN 2 Phase 3 trial of LYR-210 in CRS expected in Q2 2025.
- Positive post-hoc data from ENLIGHTEN 1 extension in polyp cohort; FDA alignment on registration path for CRSwNP.
- Planned reverse stock split to maintain Nasdaq listing; requires shareholder approval in Q2 2025.
- R&D expenses decreased to $43.8M from $48.0M due to trial completions and workforce reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000095017025038742/0000950170-25-038742-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000095017025038742/lyra-20250313.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-038742

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer